[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myasthenia-gravis-generalised\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myasthenia-gravis-generalised":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100595523","detecting-fatigue-from-voice-in-generalised-myasthenia-gravis-100595523",false,"NCT07033559","Detecting Fatigue From Voice in Generalised Myasthenia Gravis","Remote Digital Voice Biomarkers for Central Fatigue Detection in Generalised Myasthenia Gravis: An Online Single-Cohort Observational Study","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Self-reported generalised Myasthenia Gravis diagnosis confirmed by healthcare provider for ≥6 months\n* Disease stability for ≥6 months (no hospitalisations, medication changes, or significant symptom worsening)\n* English as first language\n* Residence in US or UK\n* Vision adequate for screen reading (with aid or correction if necessary)\n* Access to internet-connected device with compatible browser and microphone\n* Adequate internet connectivity (≥5 Mbps download, ≥3 Mbps upload)\n* Ability to complete twice-daily assessments during specified time windows\n* Signed electronic informed consent\n\nExclusion Criteria:\n\n* Pure ocular Myasthenia Gravis\n* Diagnosed mild cognitive impairment or dyslexia\n* Speech or hearing impairments affecting voice recording\n* Unable to provide credible diagnostic information (healthcare provider diagnosis, antibody test results, current medications)\n* Major inconsistencies in reported medical history\n* Unsigned informed consent","ALL","18 Years",{"count":19,"type":20},240,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn if computer analysis of voice recordings can detect a type of exhaustion called \"central fatigue\" in adults with generalised myasthenia gravis.\n\nThe main questions it aims to answer are:\n\n1. Can advanced voice analysis accurately tell when participants are experiencing deep exhaustion based on how they speak?\n2. How easy and acceptable is voice-based fatigue monitoring for people with myasthenia gravis?\n\nParticipants will:\n\n1. Record themselves reading short passages and answering questions out loud twice daily (morning and evening), twice a week, for 4 weeks.\n2. Answer brief questionnaires about their energy levels, mood, and myasthenia gravis symptoms during each session.\n3. Use their own devices (computer, tablet, or smartphone) to complete all study activities online from home.",[24],"Myasthenia Gravis Generalised",[26,27,28,29,30,31,32],"myasthenia gravis","generalised myasthenia gravis","fatigue","voice biomarkers","digital health","speech analysis","artificial intelligence","NOT_YET_RECRUITING","2026-01-27",{"date":36,"type":37},"2026-01-28","ACTUAL",{"date":39,"type":20},"2026-02",{"date":41,"type":20},"2026-12",{"name":43,"class":44},"Thymia Limited","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100618882","proteomic-changes-in-patients-with-myasthenia-gravis-and-ravulizumab-100618882","NCT07337395","Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab","Identification of Proteomic Changes in Patients With Generalized Myasthenia Gravis Treated With Ravulizumab: Insights Into Neuromuscular Junction Regeneration","PROMPT","Inclusion Criteria:\n\n* Age ≥18 years;\n* Diagnosis of generalized anti-AChR positive Myasthenia Gravis;\n* Need for therapy with Ravulizumab drugs according to the therapeutic indications approved by AIFA;\n* Signed informed consent to the study.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* Concomitant autoimmune diseases;\n* Insufficient availability of clinical information;\n* Ongoing neoplasia or infection at the time of biological sample collection",{"count":54,"type":20},24,"Myasthenia gravis (MG) is an autoimmune neuromuscular disorder primarily caused by antibodies targeting postsynaptic components of the neuromuscular junction, most commonly the acetylcholine receptor (AChR). In AChR-positive generalized MG, IgG1 and IgG3 antibodies activate the classical complement pathway, leading to membrane attack complex-mediated damage of the postsynaptic membrane and impaired neuromuscular transmission. Complement inhibition has therefore emerged as an effective therapeutic strategy.\n\nRavulizumab, a long-acting monoclonal antibody targeting complement component C5, has demonstrated clinical efficacy in reducing disease severity in patients with AChR-positive generalized MG. However, clinical responses to complement inhibition remain heterogeneous, and reliable biomarkers to monitor treatment response and neuromuscular junction recovery are currently lacking.\n\nBlood-based proteomics represents a powerful approach for identifying molecular changes associated with disease activity and treatment response. In particular, aptamer-based proteomic platforms such as the SomaScan® assay allow high-throughput, highly sensitive quantification of thousands of circulating proteins from small volumes of plasma or serum.\n\nThe primary aim of this study is to identify proteomic changes in patients with generalized MG treated with Ravulizumab, with a specific focus on proteins involved in neuromuscular junction regeneration and repair. By leveraging advanced proteomic technologies in a real-world clinical setting, this study seeks to identify biomarkers that may help monitor treatment response, guide optimization of concomitant immunosuppressive therapies, and improve patient stratification. Ultimately, the identification of molecular pathways associated with neuromuscular junction regeneration may open new therapeutic perspectives for autoimmune neuromuscular disorders.",[24],[58,59,60],"Myasthenia Gravis","Ravulizumab","Proteomic changes","2026-01-07",{"date":63,"type":37},"2026-01-13",{"date":65,"type":20},"2026-01",{"date":67,"type":20},"2028-01",{"name":69,"class":70},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":81,"studyType":21,"phases":4,"briefSummary":82,"conditions":83,"keywords":95,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":71},"100563559","myasthenia-gravis-foundation-of-america-global-mg-patient-registry-100563559","NCT06617741","Myasthenia Gravis Foundation of America Global MG Patient Registry","MGFAPR","Inclusion Criteria:\n\n* age over 18\n* positive MG diagnosis\n\nExclusion Criteria:\n\n* age under 18\n* misdiagnosed with MG",{"count":80,"type":20},3800,"15 Years","The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States. The main questions it aims to answer are:\n\n* How and when are people with MG diagnosed?\n* What are the most common symptoms associated with MG?\n* What treatments are being used to treat MG?\n* What are the impacts of MG on activities of daily living, employment and quality of life?\n* What are the experiences with exacerbation, hospitalization and healthcare access for people with MG? Participants will answer a survey to enroll in the study, and be invited to fill out an update survey twice a year.",[84,85,86,87,88,24,89,90,91,92,93,58,94],"Myasthaenia Gravis","Myasthenia","Myasthenia Gravis Associated with Thymoma","Myasthenia Gravis Crisis","Myasthenia Gravis Exacerbations","Myasthenia Gravis with Exacerbation (Disorder)","Myasthenia Gravis, Adult Form","Myasthenia Gravis, Generalized","Myasthenia Gravis, Ocular","Myasthenia Gravis, Thymectomy","Myasthenia Gravis, MuSK",[96,97,98,99,26],"myasthenia","patient registry","MGFA","Myasthenia Gravis Foundation of America","RECRUITING","2024-09-26",{"date":103,"type":37},"2024-09-27",{"date":105,"type":37},"2013-10-12",{"date":107,"type":20},"2029-09-19",{"name":99,"class":70}]